Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52  Weeks Assessed Using a Matching-Adjusted Indirect Comparison

ConclusionsAccording to MAICs, bimekizumab demonstrated greater or comparable efficacy on ACR50/70 and MDA outcomes than guselkumab in patients with PsA who were bDMARD-na ïve and TNFi-IR at week 48/52. Bimekizumab had a more favorable likelihood than guselkumab in achieving more stringent treatment outcomes.Trial RegistrationsNCT03895203, NCT03896581, NCT04009499, NCT03158285, NCT03796858.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research